Use of HPV testing for cervical screening in vaccinated women - Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study

International Journal of Cancer

Volumn 138, Issue 12, 2016, Pages 2922-2931

  Bhatia, Ramya ^a   Kavanagh, Kimberley ^b   Cubie, Heather Ann ^a,c   Serrano, Itziar ^a   Wennington, Holli ^a   Hopkins, Mark ^d   Pan, Jiafeng ^b   Pollock, Kevin G ^e   Palmer, Tim J ^c   Cuschieri, Kate ^f  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

cervical screening; clinically validated HPV tests; HPV; HPV immunisation

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LONGITUDINAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; YOUNG ADULT; EARLY CANCER DIAGNOSIS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; SCOTLAND; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SCOTLAND; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84960970884     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30030     Document Type: Article

References (27)

1. Drolet M, Bénard É, Boily M-C, et al., Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565-80.
2. Kavanagh K, Pollock KGJ, Potts A, et al., Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110: 2804-11.
3. Tabrizi SN, Brotherton JML, Kaldor JM, et al., Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14: 958-66.
4. Ronco G, Dillner J, Elfström KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet Lond Engl 2014;383: 524-32.
5. Arbyn M, Snijders PJF, Meijer CJLM, et al., Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2015; 21: 817-26.
6. Choi YH, Chapman R, Gay N, Jit M., Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine 2012; 30: 3383-8.
7. Available at: http://www.isdscotland.org/health-topics/cancer/cervical-screening/.
8. HPV Immunisation Uptake Rates HPV Immunisation Programme-School Year 2013/14 Publication date-30 September 2014. Available at: http://www.isdscotland.org/health-topics/child-health/publications/
9. Pollock KGJ, Kavanagh K, Potts A, et al., Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111: 1824-30.
10. Cameron RL, Kavanagh K, Pan J, et al., Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland. Emerg Infect Dis. 2016; 22: 56-64.
11. Kavanagh K, Sinka K, Cuschieri K, et al., Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 2013; 13:519.
12. IARC Monographs on the evaluation of carcinogenic risks to humans. Available at: http://monographs.iarc.fr/ENG/Monographs/vol100B/
13. Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp01.html.
14. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.html
15. Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al., HPV immunisation and cervical screening-confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer [Internet]. 2016 Feb 4 [cited 2016 Feb 17]; Available from: http://www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2015474a.html
16. Arbyn M, Roelens J, Cuschieri K, et al., The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer J Int Cancer 2013;132: 101-8.
17. Monsonego J, Hudgens MG, Zerat L, et al., Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecol Oncol 2012; 125: 175-80.
18. Mori S, Nakao S, Kukimoto I, et al., Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011; 102: 1223-7.
19. Rijkaart DC, Berkhof J, van Kemenade FJ, et al., Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer J Int Cancer 2012;130: 602-10.
20. Khan MJ, Castle PE, Lorincz AT, et al., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
21. Thomsen LT, Frederiksen K, Munk C, et al., Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. Int J Cancer J Int Cancer 2015; 137: 193-203.
22. Palmer TJ, Robertson C, Cuschieri K, et al., Effect of HR-HPV immunisation on the performance of cervical cytology. In: OC12, p206. Sevilla, Spain; February 4th to 7th.
23. Kahn JA, Brown DR, Ding L, et al., Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. Pediatrics 2012; 130: e249-56.
24. Waters EK., Aggregation and competitive exclusion: explaining the coexistence of human Papillomavirus types and the effectiveness of limited vaccine conferred cross-immunity. Acta Biotheor 2012; 60: 333-56.
25. Cornall AM, Phillips S, Cummins E, et al., In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol Methods 2015; 214: 10-4.
26. Stanczuk G, Baxter G, Currie H, et al., Effect of catch up vaciantion on HPV prevalence in routine cervical screening. In: OC3-7, p157. Sevilla, Spain; 2015.
27. O'Leary MC, Sinka K, Robertson C, et al., HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer 2011; 104: 1221-6.